UroGen Pharma Ltd. — Director's Dealing 2024

Feb 5, 2024

SEC Form 4/A — Form 4/A

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-01-31

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-01	Ordinary Shares	S	417	$15.78	Disposed	18824	Direct
2024-02-01	Ordinary Shares	S	1248	$15.78	Disposed	20076	Direct
2024-02-01	Ordinary Shares	S	3328	$15.78	Disposed	23414	Direct

Footnotes

F1: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024.

F2: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024.